drugset / Trial / NCT02246920

Clinical Equivalence Study of Fluticasone Propionate Nasal Spray, 50 mcg/Actuation vs. Flonase in Allergic Rhinitis Patients

NCT02246920

Phase 3 Terminated 1474 enrolled Teva Pharmaceuticals USA
RandomizedParallel-groupQuadruple-blindOther

Summary

This double-blind, randomized, placebo-controlled, parallel group, multi-site study has been designed to compare the safety and efficacy of a generic Fluticasone propionate Nasal Spray, 50 mcg (Teva Pharmaceuticals USA) to the FDA Reference Listed Drug, Flonase® (fluticasone propionate) 50 mcg nasal spray (GlaxoSmithKline), in the relief of the signs and symptoms of Seasonal Allergic Rhinitis. Additionally, both the test and reference formulations will be tested for superiority against a placebo nasal spray.

Timeline

Start
2014-03-01
Primary completion
2014-07-14
Completion
2014-07-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluticasone propionate Other / unclassified 200 ug Intranasal